ECSP034445A - IMIDAZOL DERIVATIVES - Google Patents
IMIDAZOL DERIVATIVESInfo
- Publication number
- ECSP034445A ECSP034445A EC2003004445A ECSP034445A ECSP034445A EC SP034445 A ECSP034445 A EC SP034445A EC 2003004445 A EC2003004445 A EC 2003004445A EC SP034445 A ECSP034445 A EC SP034445A EC SP034445 A ECSP034445 A EC SP034445A
- Authority
- EC
- Ecuador
- Prior art keywords
- formula
- compounds
- syndrome
- pharmaceutical compositions
- conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
La invención proporciona compuestos de la fórmula I; en la que R1, R2, R3, R4, son como se han definido y sus sales farmacéuticamente aceptables, Se indica que los compuestos de fórmula I tiene actividad inhibidora de cdk5, cdk2 y GSK-3. También se describen composiciones farmacéuticas y procedimientos que comprenden compuestos de fórmula I para tratar y prevenir enfermedades y afecciones que comprenden un crecimiento celular anormal, tal como el cáncer , enfermedades y afecciones neurodegenerativas y las afectadas por la neurotrasmisión de dopamina. También se describen composiciones farmacéuticas y procedimientos que comprenden compuestos de fórmula I para tratar la fertilidad masculina y motilidad de los espermatozoides; diabetes mellitus; disminución de la tolerancia a la glucosa; síndrome metabólico o síndrome X, síndrome de ovarios poliquísticos; adipogénesis y obesidad, miogénesis y debilidad , por ejemplo, atrofia muscular y/o caquexia asociada con quemaduras, reposo en cama, inmovilización de miembros o cirugía toráxica abdominal y/u ortopédica mayor, sepsi, pérdida de cabello, debilitamiento del cabello y calvicie, e inmunodeficiencia.The invention provides compounds of the formula I; wherein R1, R2, R3, R4, are as defined and their pharmaceutically acceptable salts, It is indicated that the compounds of formula I have inhibitory activity of cdk5, cdk2 and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula I for treating and preventing diseases and conditions comprising abnormal cell growth, such as cancer, neurodegenerative diseases and conditions and those affected by dopamine neurotransmission are also described. Pharmaceutical compositions and methods comprising compounds of formula I for treating male fertility and sperm motility are also described; Mellitus diabetes; decreased glucose tolerance; metabolic syndrome or syndrome X, polycystic ovarian syndrome; adipogenesis and obesity, myogenesis and weakness, for example, muscle atrophy and / or cachexia associated with burns, bed rest, limb immobilization or major abdominal and / or orthopedic thoracic surgery, sepsi, hair loss, hair weakening and baldness, and immunodeficiency.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22172400P | 2000-07-31 | 2000-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP034445A true ECSP034445A (en) | 2003-03-10 |
Family
ID=22829075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2003004445A ECSP034445A (en) | 2000-07-31 | 2003-01-22 | IMIDAZOL DERIVATIVES |
Country Status (36)
| Country | Link |
|---|---|
| EP (1) | EP1305295A1 (en) |
| JP (2) | JP4166084B2 (en) |
| KR (1) | KR20030019644A (en) |
| CN (1) | CN1444567A (en) |
| AP (1) | AP2001002232A0 (en) |
| AR (1) | AR032629A1 (en) |
| AU (1) | AU2001270944A1 (en) |
| BG (1) | BG107469A (en) |
| BR (1) | BR0112862A (en) |
| CA (1) | CA2418115A1 (en) |
| CR (1) | CR6861A (en) |
| CZ (1) | CZ2003225A3 (en) |
| DO (1) | DOP2001000220A (en) |
| EA (1) | EA200300097A1 (en) |
| EC (1) | ECSP034445A (en) |
| EE (1) | EE200300049A (en) |
| GT (1) | GT200100147A (en) |
| HR (1) | HRP20030048A2 (en) |
| HU (1) | HUP0303069A3 (en) |
| IL (1) | IL153787A0 (en) |
| IS (1) | IS6662A (en) |
| MA (1) | MA26932A1 (en) |
| MX (1) | MXPA03000939A (en) |
| NO (1) | NO20030472L (en) |
| NZ (1) | NZ523272A (en) |
| OA (1) | OA12345A (en) |
| PA (1) | PA8523701A1 (en) |
| PE (1) | PE20020337A1 (en) |
| PL (1) | PL365134A1 (en) |
| PY (1) | PY0117895A (en) |
| SK (1) | SK1042003A3 (en) |
| SV (1) | SV2002000571A (en) |
| TN (1) | TNSN01114A1 (en) |
| UY (1) | UY26862A1 (en) |
| WO (1) | WO2002010141A1 (en) |
| ZA (1) | ZA200300819B (en) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2298311B1 (en) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| DK1478358T3 (en) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylate for the treatment of diseases characterized by abnormal angiogenesis |
| US7465736B2 (en) | 2002-06-14 | 2008-12-16 | Laboratoires Serono S.A. | Azole methylidene cyanide derivatives and their use as protein kinase modulators |
| US7141561B2 (en) | 2002-07-25 | 2006-11-28 | Sanofi-Aventis Deutschland Gmbh | Substituted diaryl heterocycles, process for their preparation and their use as medicaments |
| DE10233817A1 (en) * | 2002-07-25 | 2004-02-12 | Aventis Pharma Deutschland Gmbh | Substituted diaryl heterocycles, process for their preparation and their use as medicaments |
| GB0308968D0 (en) * | 2003-04-17 | 2003-05-28 | Glaxo Group Ltd | Medicaments |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| PL1663978T3 (en) | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| AP2379A (en) * | 2004-03-23 | 2012-03-08 | Pfizer Prod Inc | Imidazole compounds for the treatment of neurodegenerative disorders. |
| US7838524B2 (en) | 2004-04-30 | 2010-11-23 | Bayer Healthcare Llc | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| PT1791811E (en) | 2004-09-21 | 2010-02-23 | Astellas Pharma Inc | Aminoalcohol derivatives |
| US20080207594A1 (en) | 2005-05-04 | 2008-08-28 | Davelogen Aktiengesellschaft | Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders |
| EP2275096A3 (en) | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenesis via modulation of the muscarinic receptors |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP1940802A2 (en) | 2005-09-22 | 2008-07-09 | Pfizer Products Inc. | Imidazole compounds for the treatment of neurological disorders |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| AU2007207743B2 (en) | 2006-01-18 | 2010-07-08 | Amgen Inc. | Thiazole compounds as protein kinase B (PKB) inhibitors |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| WO2008046919A2 (en) | 2006-10-21 | 2008-04-24 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
| ES2418457T3 (en) * | 2008-04-24 | 2013-08-13 | Abbott Gmbh & Co. Kg | Derivatives of 1- (7- (hexahydropyrrolo [3,4-c] pyrrol-2 (1H) -yl) quinolin-4-yl) -3- (pyrazin-2-yl) urea and related compounds such as glycogen synthase inhibitors kinase 3 (GSK-3) |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US9266855B2 (en) | 2010-09-27 | 2016-02-23 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| EP2928474B1 (en) | 2012-12-07 | 2018-11-14 | ChemoCentryx, Inc. | Diazole lactams |
| JP6306607B2 (en) | 2012-12-21 | 2018-04-04 | ケモセントリックス，インコーポレイティド | Diazole amide |
| US10653672B2 (en) | 2014-02-07 | 2020-05-19 | National University Corporation Tokyo Medical And Dental University | Myogenesis promotor, muscle atrophy inhibitor, medical composition and TAZ activator |
| WO2017040611A1 (en) * | 2015-08-31 | 2017-03-09 | Nutramax Laboratories, Inc. | Compositions comprising magnolia, phellodendron, theanine and/or whey protein |
| GB201605126D0 (en) * | 2016-03-24 | 2016-05-11 | Univ Nottingham | Inhibitors and their uses |
| IL261998B2 (en) | 2016-04-07 | 2023-03-01 | Chemocentryx Inc | Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
| CN107698567B (en) * | 2017-10-25 | 2020-09-15 | 西南大学 | Isatin azole alcohol compound and preparation method and medical application thereof |
| CN112823151B (en) * | 2018-07-03 | 2024-11-15 | 艾福姆德尤股份有限公司 | Compounds and compositions for treating diseases associated with STING activity |
| WO2020163812A1 (en) | 2019-02-08 | 2020-08-13 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| GB201908424D0 (en) | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Novel compounds |
| US11884634B2 (en) | 2019-08-09 | 2024-01-30 | Pfizer Inc. | Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide |
| ES3055762T3 (en) | 2019-08-09 | 2026-02-16 | Pfizer | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof |
| US20240132485A1 (en) * | 2020-10-16 | 2024-04-25 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
| CN112250636A (en) * | 2020-11-09 | 2021-01-22 | 广西科技大学 | 5-aminoimidazole compound and synthesis method thereof |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| MX2024002590A (en) | 2021-09-01 | 2024-03-22 | Springworks Therapeutics Inc | Synthesis of nirogacestat. |
| US11504354B1 (en) | 2021-09-08 | 2022-11-22 | SpringWorks Therapeutics Inc.. | Chlorinated tetralin compounds and pharmaceutical compositions |
| CN116983313B (en) * | 2023-07-13 | 2026-01-27 | 四川大学 | New application of NU6300 |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5401851A (en) * | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
| US5760246A (en) * | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| ZA987383B (en) * | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
| ZA987385B (en) * | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
| DE69919707T2 (en) * | 1998-06-19 | 2005-09-01 | Chiron Corp., Emeryville | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS |
| WO2000021550A2 (en) * | 1998-10-13 | 2000-04-20 | President And Fellows Of Harvard College | Methods and compositions for treating neurodegenerative diseases |
| CO5160260A1 (en) * | 1999-02-19 | 2002-05-30 | Lilly Co Eli | SECRETAGOGOS OF THE HORMONE OF GROWTH DERIVED FROM IMI- DAZOL 1,4- SUBSTITUTED |
| DE69912808T2 (en) * | 1999-12-08 | 2004-09-30 | Centre National De La Recherche Scientifique (C.N.R.S.) | Use of hymenialdisine and its derivatives for the preparation of therapeutic agents |
-
2001
- 2001-07-23 GT GT200100147A patent/GT200100147A/en unknown
- 2001-07-23 PY PY200100117895A patent/PY0117895A/en unknown
- 2001-07-25 AU AU2001270944A patent/AU2001270944A1/en not_active Abandoned
- 2001-07-25 EA EA200300097A patent/EA200300097A1/en unknown
- 2001-07-25 HR HR20030048A patent/HRP20030048A2/en not_active Application Discontinuation
- 2001-07-25 SK SK104-2003A patent/SK1042003A3/en not_active Application Discontinuation
- 2001-07-25 JP JP2002516273A patent/JP4166084B2/en not_active Expired - Fee Related
- 2001-07-25 EP EP01949833A patent/EP1305295A1/en not_active Withdrawn
- 2001-07-25 CN CN01813397A patent/CN1444567A/en active Pending
- 2001-07-25 BR BR0112862-0A patent/BR0112862A/en not_active IP Right Cessation
- 2001-07-25 MX MXPA03000939A patent/MXPA03000939A/en active IP Right Grant
- 2001-07-25 IL IL15378701A patent/IL153787A0/en unknown
- 2001-07-25 WO PCT/IB2001/001335 patent/WO2002010141A1/en not_active Ceased
- 2001-07-25 PL PL01365134A patent/PL365134A1/en not_active Application Discontinuation
- 2001-07-25 KR KR10-2003-7001455A patent/KR20030019644A/en not_active Ceased
- 2001-07-25 CZ CZ2003225A patent/CZ2003225A3/en unknown
- 2001-07-25 OA OA1200300017A patent/OA12345A/en unknown
- 2001-07-25 NZ NZ523272A patent/NZ523272A/en unknown
- 2001-07-25 HU HU0303069A patent/HUP0303069A3/en unknown
- 2001-07-25 EE EEP200300049A patent/EE200300049A/en unknown
- 2001-07-25 CA CA002418115A patent/CA2418115A1/en not_active Abandoned
- 2001-07-25 PE PE2001000752A patent/PE20020337A1/en not_active Application Discontinuation
- 2001-07-26 AP APAP/P/2001/002232A patent/AP2001002232A0/en unknown
- 2001-07-27 SV SV2001000571A patent/SV2002000571A/en not_active Application Discontinuation
- 2001-07-27 DO DO2001000220A patent/DOP2001000220A/en unknown
- 2001-07-30 AR ARP010103637A patent/AR032629A1/en unknown
- 2001-07-30 TN TNTNSN01114A patent/TNSN01114A1/en unknown
- 2001-07-30 UY UY26862A patent/UY26862A1/en not_active Application Discontinuation
- 2001-07-31 PA PA20018523701A patent/PA8523701A1/en unknown
-
2002
- 2002-12-18 CR CR6861A patent/CR6861A/en not_active Application Discontinuation
- 2002-12-19 IS IS6662A patent/IS6662A/en unknown
-
2003
- 2003-01-16 BG BG107469A patent/BG107469A/en unknown
- 2003-01-20 MA MA27004A patent/MA26932A1/en unknown
- 2003-01-22 EC EC2003004445A patent/ECSP034445A/en unknown
- 2003-01-29 ZA ZA200300819A patent/ZA200300819B/en unknown
- 2003-01-30 NO NO20030472A patent/NO20030472L/en not_active Application Discontinuation
-
2008
- 2008-05-19 JP JP2008131176A patent/JP2008255123A/en not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR6861A (en) | IMIDAZOL DERIVATIVES | |
| ECSP034480A (en) | PIRAZOL DERIVATIVES | |
| BR0201691A (en) | Thiazole Derivatives | |
| NO20064412L (en) | Condensed heterocycle derivative, medical composition containing the same and medical use thereof | |
| GEP20267861B (en) | Anti-viral compounds | |
| PA8593101A1 (en) | COMPOSITIONS FOR THE TREATMENT OF ABNORMAL CELL GROWTH | |
| NO20081844L (en) | Therapeutic compounds | |
| NO20031024D0 (en) | Bicyclic pyrrolyl amides as glucogenic phosphorylase inhibitors | |
| NO20053748L (en) | Pyrrolopyridazine derivatives. | |
| EP1609798A4 (en) | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | |
| CO4810375A1 (en) | DERIVATIVES OF 9-AMINO-3-KETO Erythromycin | |
| GT200100201A (en) | DERIVATIVES OF PIRAZOL FOR THE TREATMENT DER VIRIC DISEASES. | |
| NO20023977D0 (en) | 8,8A-dihydroindo (1,2-D) thiazole derivatives having a sulfonamide or sulfone substituted at the 2-position, a process of preparation thereof and use as a drug | |
| PA8568101A1 (en) | INDOLIL-UREA DERIVED FROM USEFUL TIENOPIRIDINS AS ANTIANGIOGEN AGENTS, AND PROCEDURES FOR USE | |
| NO20064010L (en) | Indazole derivatives and pharmaceutical preparations contain such | |
| DK1124841T3 (en) | Substituted phenylalkenoylguanidines, processes for their preparation, use thereof as drugs or diagnostics and drugs containing them | |
| BRPI0518785A2 (en) | 7-membered ring compound and method of production and pharmaceutical application thereof | |
| DOP2002000519A (en) | PROCEDURE FOR THE PREPARATION OF SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
| PA8450901A1 (en) | Erythromycin derivatives | |
| ECSP055673A (en) | DERIVATIVES OF 4- (3,5-DICIANOPHENOXI) PIRAZOL FOR USE AS REVERSE TRANSCRIPTASE MODULATORS IN HIV TREATMENT | |
| AR049343A1 (en) | THIOETER DERIVATIVES, THEIR OBTAINING AND USE OF THE SAME AS PHARMACEUTICAL AGENTS | |
| ES2136013B1 (en) | DERIVATIVES OF TIENO AND PIRAZOLO (1,2,4) THIADIAZINE-1,1-DIOXIDE PHARMACOLOGICALLY ACTIVE. | |
| ECSP003665A (en) | BENCIMIDAZOL DERIVATIVES, SUBSTITUTES, PROCEDURE FOR PREPARATION AND EMPLOYMENT AS MEDICATIONS | |
| UY29135A1 (en) | DERIVATIVES OF N-METHYLBENZENOSULFONAMIDE 4 AND N SUBSTITUTES, PREPARATION PROCEDURES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS | |
| ECSP982501A (en) | Erythromycin derivatives |